Objective: Previous studies suggest that darbepoetin might stimulate erythropoiesis in preterm neonates more effectively if injected subcutaneously (s.c.) than if infused intravenously (i.v.). It has been postulated that this is because very high plasma concentrations after i.v. dosing result in urinary loss of the drug. However, this theory has not been tested systematically, and no direct comparisons have been made between s.c. and i.v. dosing of darbepoetin in preterm neonates.
Introduction
Darbepoetin is longer acting and more potent than recombinant erythropoietin (rEpo), 1 and it may be a more cost effective alternative to treating certain anemic patients. 2 Darbepoetin can be administered to preterm infants by either intravenous (i.v.) or subcutaneous (s.c.) route of administration. 3, 4 Our recent studies, and unpublished data cited by the manufacturer, 5 suggest that s.c. dosing may be more effective in stimulating erythropoiesis than i.v. dosing, but this has not been tested directly. One reason given to explain why i.v. dosing may be less effective is very high plasma concentrations following i.v. administration, accompanied by substantial loss of drug into the urine. In contrast, the lower and more sustained plasma concentrations following s.c. dosing might result in less urinary loss of drug. 6, 7 Urinary excretion of natural Epo by preterm neonates was first reported by McIntosh, in an era before rEpo was available. 6 Later, Buhrer et al. 7 administered rEpo i.v. to one preterm twin and s.c. to the other, and then measured Epo in the urine of both over the next 20 h. The twin with the s.c. dosing had negligible Epo measured in the urine but the twin with the i.v. dose had substantial concentrations. However, no studies have systematically examined the urinary excretion of rEpo or darbepoetin among groups of preterm neonates after i.v. or s.c. dosing. Based on the reports of McIntosh 6 and Buhrer et al., 7 we hypothesized that urinary wastage of darbepoetin would occur after i.v. dosing and not after s.c. dosing. The present study was designed to compare urinary loss of darbepoetin after i.v. vs s.c. administration to preterm neonates, and to compare the reticulocyte response following i.v. vs s.c. dosing.
Methods

Participants
Patients were deemed eligible to participate if they were born p32 weeks gestation, with a birth weight p1500 g, and had a hemoglobin (Hgb) of p10.5 g/dl at the time darbepoetin was administered. Subjects received a single 4 mg/kg dose of darbepoetin (Aranesp, Amgen Inc., Thousand Oaks, CA). The darbepoetin was given i.v. if the patient had an i.v. in place and it was given s.c. if they did not. When given i.v., it was mixed in 4 ml sterile normal saline and infused using a 4-h constant infusion of 1 ml/h. When given s.c., it was administered in the thigh by the bedside neonatal staff nurse. Patients were not eligible if they were recognized to have a chronic anemia, other than the anemia of prematurity. This was a pilot study with a convenience sample of n ¼ 10. The study was approved by the Intermountain Healthcare Institutional Review Board.
Urine collection
Urine was collected from cotton balls placed in the diapers. The diapers, including the cotton balls, were changed every 3 h and were weighed to estimate the volume of urine. Any diapers that contained stool were also weighted, but the weight of stool was estimated and subtracted. Urine was collected immediately before the dose of darbepoetin was given. Urine was then collected beginning at the time of the dose and for the next 48 h. From the cotton balls about 0.5 ml of urine was aspirated using a syringe. Only cotton balls that were not contaminated with stool were aspirated. The urine was transferred immediately to a freezercompatible specimen tube (1 ml) and frozen at À201C. The Epo concentration in each urine specimen was quantified by enzymelinked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN). The ELISA measures darbepoetin as well as Epo. The minimum detectable concentration is 0.6 mU/ml (0.0006 U/ml), with inter-and intra-assays within 5%. The ELISAs were performed by individuals who had no information about the assignment group (i.v. vs s.c.).
Blood studies
The immature reticulocyte fraction (IRF) and the absolute reticulocyte count (ARC), obtained before and 96 h after the dosing, were determined using the Beckman Coulter GENS System (Beckman Coulter Inc., Brea, CA). The IRF assesses reticulocyte maturity based on staining intensity of reticulocytes, which is proportional to RNA content. 8 The ARC was calculated automatically by multiplying the erythrocyte concentration by the reticulocyte percentage.
Statistical considerations
Descriptive statistics were calculated using Microsoft Excel. Means and standard deviations were used to express values in groups that were normally distributed, and medians and ranges to express values in groups that were not. The total amount of darbepoetin detected in the urine, over the 48-h study period, was estimated by multiplying the urine output (from weighed diapers) by the concentration of Epo measured in each of the various urine specimens. The percentage of the dose administered (i.v. or s.c.) that was detected in the urine in the first 48 h after dosing was calculated by dividing the total amount of drug recovered in the urine during 48 h (expressed in U) by the amount of drug administered (expressed in U; 4 mg/kg Â body wt Â 400 U/mg).
Results
In the 6-week period, 14 February to 29 March 2006, 10 eligible neonatal intensive care unit (NICU) patients not previously enrolled in a conflicting research study were enrolled in this study. All patients p32 weeks gestation, with a birth weight p1500 g, and with a Hgb of p10.5 g/dl, who were not participating in a conflicting study were enrolled and none of these 10 dropped out of the study. All 10 received a single dose of 4 mg/kg darbepoetin. Some of the post-dose urine samples were inadvertently not collected on one patient (s.c. #1), and another patient (s.c. #4) did not have a post-dose IRF value recorded because of machine error.
Demographics of the study subjects are shown in Table 1 . There was no difference in birth weight or gestational age at delivery between the groups who received darbepoetin i.v. and those who received it s.c. However, at the time the dose was given, those who received an i.v. dose were significantly younger and lighter weight than were those who received an s.c. dose.
No adverse events were reported on any of the 10 subjects. Specifically, no new rashes, and no increase or decrease in blood pressure or heart rate, or need for supplemental oxygen was observed in relation to the doses. Table 2 lists the IRF, ARC and reticulocyte percentage before and 96 h after the darbepoetin dose. All three reticulocyte parameters increased in both the i.v. and the s.c. groups. No differences in magnitude of reticulocyte response at 96 h were observed between the i.v. and s.c. recipients.
The length of time urine specimens were frozen prior to (batched) ELISA analysis ranged from 2 to 8 weeks. Before dosing, none of the 10 patients had any urinary Epo detected. During the 48 h following i.v. dosing, none had any urinary Epo detected. During the 48 h following s.c. dosing, minimally detectable concentrations of Epo were identified in s.c. #2 and s.c. #5. The Epo concentrations detected in these urine specimens were all <0.010 U/ml. One patient (s.c. #4) had more than minimally detectable urinary Epo, totaling 3.574 U in 191 ml of urine during the 48 h period. Thus, the maximal urinary loss of drug, calculated as a percentage of the drug administered, was only 0.13% (loss ¼ 3.57 U; administered ¼ 2928 U) (4 mg/ kg Â 1.83 kg ¼ 7.32 mg Â 400 U/mg ¼ 2928 U). This patient had the smallest birth weight (400 g) and was the oldest at the time of study (93 days) of any patient studied. This patient had normal renal function studies (blood urea nitrogen (BUN), 13 mg/dl and creatinine 0.3 mg/dl) and a normal urine output (2.4 ml/kg/h).
Discussion
Buhrer et al. 7 administered single doses of rEpo (250 U/kg) to two, 2-week-old, 27-week gestation, twins. One twin received the dose i.v., whereas the other received the dose s.c. Over the following 20 h, serial urine determinations were performed on both, which showed a substantial loss of Epo into the urine after the i.v. dose, but not after the s.c. dose. Our present study was somewhat similar to the Buhrer and Obladen study, but was performed in 10 premature neonates: five of which received an i.v. dose and five an s.c. dose of darbepoetin. We used a darbepoetin dose of 4 mg/kg on the basis of our previous pharmacokinetic studies. 3, 4 This dose is a much higher unit dose than that given by Buhrer and Obladen. If the conversion factor of 1 mg darbepoetin ¼ 400 U rEpo is used, 4, 5 our dose was 6.4 times higher than the Buhrer and Obladen dose. If the conversion factor suggested by Jelkmann 9 is used, which is 1 mg darbepoetin ¼ 200 U rEpo, our dose was 3.2 times higher than the Buhrer and Obladen dose. 
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The five patients to whom we administered an i.v. dose were selected because they already had an i.v. in place. Likewise, the five patients to whom we administered an s.c. dose were selected because they did not have an i.v. in place. At delivery, these two groups were similar to each other in birth weight and gestational age, but at the time of the darbepoetin dose, the i.v. recipients were younger and lighter. We realize that selection of study groups based on the presence vs absence of an i.v. would result in groups that were dissimilar in certain ways. Specifically, those with an i.v. in place would tend to be younger. However, we selected this criterion, rather than a completely randomized approach, because it better reflects the potential clinical application of the results. Namely, i.v. dosing might be more likely for neonates who have an i.v. in place, and s.c. dosing might be more likely for neonates who do not.
We collected urine from cotton balls that were placed in the diapers. A more accurate method would have involved placement of Foley catheters, but we judged this to be an unwarranted risk for study participants. Using the cotton ball method, we did not detect any Epo in the urine of any of the patients prior to the darbepoetin administration. This is similar to the report of Buhrer and Obladen, observing no Epo in the urine of one twin and minimally detectible amounts in the other. 7 Also similar to the Buhrer and Obladen report, following the s.c. doses we detected minimal Epo in urine samples. Only one of our patients (s.c. #4) had more than trace amounts of Epo in the urine, and that patient's urinary loss amounted to less that 0.2% of the dose administered. No clear explanation is apparent for why this patient had urinary loss of drug. This was the smallest (400 g birth wt) patient in the study, and he was also the oldest (93 days) when dosed. He had a normal BUN, creatinine and urine output.
In contrast to the findings of Buher and Obladen, we detected no Epo in any of the urine specimens of any of the i.v. recipients, at any time following the dosing. Perhaps the difference between our results and theirs can be explained, at least in part, by the rate of the i.v. infusion. We infused the i.v. darbepoetin very slowly, over a 4-h period, and perhaps this prevented extremely high peek serum concentrations and subsequently prevented urinary loss. We are not aware of the length of time Buhrer and Obladen infused the drug, but we speculate that theirs was a more rapid infusion. Another possible explanation for the difference between our results and theirs is that we used darbepoetin, while they used rEpo. It might be that the molecular modification to create darbepoetin (maximum siaic-acid content 22 in darbepoetin vs 14 in rEpo) renders darbepoetin less likely than rEpo to undergo urinary loss. 9 Urinary loss of rEpo following i.v. dosing has been used as an explanation for the supposed reduced efficacy of rEpo after i.v. administration. However, in this study, we observed no reduced efficacy after i.v. administration. We speculate that a relatively slow (4 h) i.v. infusion of darbepoetin results in negligible or no urinary loss of drug, and produces erythropoietic stimulation equivalent to that following s.c. dosing. On the basis of these findings, we further speculate that if darbepoetin is to be given to a preterm infant who already has an i.v. in place, the drug can be given i.v., thus avoiding any discomfort associated with an s.c. administration.
